An observational study in Coronary Artery Disease, sponsored by Seung-Jung Park. Recruiting at 29 sites in South Korea. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Seung-Jung Park · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Coronary Artery Disease by Seung-Jung Park — 11 open to participants now, 13 under way, none of them phase 3. Coronary Artery Disease · Seung-Jung Park.
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, this one is the 4th largest by planned enrollment of the 30 observational ones that give a count, is one of 5 that started in 2011, is one of 30 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 32nd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →11 of the 59 studies in Coronary Artery Disease by Seung-Jung Park are open now, in 8 countries. Recruiting first, the newest first:
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Hong Kong, India, Japan and 2 more countries
Ages 20+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 500 across the 29 interventional studies, 2,000 across the 30 observational. Of the 46 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
3 of the studies in Coronary Artery Disease by Seung-Jung Park that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, from their registry updates:
This tab as a report to print or save as PDF → With an account.
About 20,000 patients with FFR (Fractional Flow Reserve) will be enrolled and evaluated for the natural history of coronary lesions at 2 years clinical and imaging follow-up.
This is a multicenter, prospective cohort. About 20,000 patients with FFR will be enrolled at multi centres in Korea.
Patients who had FFR measurement
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Imaging study specific exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who had FFR measurement
Target vessel failure
Time frame: 2 year after index FFR measurement
composite Cardiac Death,Non Fatal Myocardial Infarction, Target Vessel Revascularization, and Indeterminate events
Time frame: at 2 year after index FFR measurement
Death (all cause and cardiac)
Time frame: at 2 year after index FFR measurement
MI
Time frame: at 2 year after index FFR measurement
Target vessel revascularization
Time frame: at 2 year after index FFR measurement
Target lesion revascularization
Time frame: at 2 year after index FFR measurement
Any re-hospitalization with a cardiac cause
Time frame: 2 year follow-up after index FFR measurement
cardiac death and myocardial infarction
Time frame: 2 year follow-up after index FFR measurement
stented lesion related event including death, myocardial infarction, repeat revascularization
Time frame: 2 year follow-up after index FFR measurement
stroke
Time frame: 2 year follow-up after index FFR measurement
stent thrombosis
Time frame: 2 year follow-up after index FFR measurement
anginal status
Time frame: 2 year follow-up after index FFR measurement
number of anti-anginal medication prescribed
Time frame: 2 year follow-up after index FFR measurement
complication of FFR measurement
Time frame: 2 year follow-up after index FFR measurement
clinical predictors of events
Time frame: 2 year follow-up after index FFR measurement
change in plaque composition (%necrotic core volume) in target segment
Time frame: 2 year follow-up after index FFR measurement
change in plaque type assessed by VH(Virtual Histology) and OCT(Optical coherence tomography)
Time frame: 2 year follow-up after index FFR measurement
change in total atheroma volume and percent atheroma volume
Time frame: 2 year follow-up after index FFR measurement
change in IVUS-measured MLA
Time frame: 2 year follow-up after index FFR measurement
change in FFR
Time frame: 2 year follow-up after index FFR measurement
Plan to share: Undecided
Started Jun 2011 (actual). Primary completion is estimated for Apr 2037, 310 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 310 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park